Neuroblastoma is the most common extracranial tumor of childhood, and 60% of patients have aggressive disease from which only 20-40% survive. Their long term goal is to gain a better molecular biologic understanding of aggressive tumors so that more effective therapies can be developed. Their previous research suggests that the proto-oncogene MYCN, the neurotrophin receptors TrkA and p75TNR, and the neurotrophin Nerve Growth Factor (NGF) have important roles in determining the behavior of neuroblastomas. Hypothesis. Aggressive neuroblastomas escape the growth inhibitory, differentiating, and apoptotic influences of TrkA and p75TNR 1) by not expressing these receptors; 2) by altering signal transduction downstream from these receptors; and/or 3) by creating a NGF/p75NTR autocrine, anti-apoptotic loop.
Specific Aims. 1) Define relationships between expression of TrkA, p75TNR , NGF, MYCN, MYCN gene status, histopathology, and clinical behavior of neuroblastomas. 2) Determine with retroviral gene transduction models if p75TNR can induce apoptosis and if a NGF/p75TNR autocrine loop enhances survival of neuroblastoma cells. 3) Determine if a naturally occurring NGF/p75TNR autocrine loop enhances survival of neuroblastoma cells. Research Design. RT-PCR quantitation of TrkA, p75TNR, NGF, and MYCN mRNA will be completed for 360 neuroblastomas. Histopathology will characterize tumors morphologically and identify proliferating and apoptotic cells and cells expressing p75TNR, TrkA, and NGF. Clinically important subsets will be defined. To assess the role of p75TNR in apoptosis, cell lines will be transduced with p75TNR in the presence of NGF, and then their dependence upon NGF for survival will be determined. Studies of p75TNR mediated signaling will emphasize roles of TrkA co-expression and of sphingomyelin/ceramide and caspases in apoptosis. To demonstrate that p75TNR and NGF can form an autocrine loop, neuroblastoma cell lines that have been transduced with p75TNR and shown to undergo apoptosis upon NGF withdrawal will be co-transduced with NGF cDNA. Approximately 60 low passage cell lines established at diagnosis will be screened to identify those expressing NGF and p75TNR (RT-PCR) and retaining sensitivity to ceramide. These will be tested with p75TNR and TrkA specific antagonists and an Ig-TrkA fusion protein to determine if they have a natural NGF/p75TNR autocrine loop that prevents apoptosis. Methods. These include quantitative RT-PCR, gene transduction, assessing clonogenic growth in microwells with digital image microscopy, immunostaining for TrkA and p75TNR selective agonist and antagonist molecules and with an Ig-TrkA fusion protein. We anticipate that this research will contribute to the understanding of neuroblastoma and ultimately to therapeutic modalities that are more effective and specific.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA022794-22
Application #
2894491
Study Section
Pathology B Study Section (PTHB)
Program Officer
Bledsoe, Marianna
Project Start
1978-02-01
Project End
2001-03-31
Budget Start
1999-04-01
Budget End
2000-03-31
Support Year
22
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Children's Hospital of Los Angeles
Department
Type
DUNS #
094878337
City
Los Angeles
State
CA
Country
United States
Zip Code
90027
Metelitsa, Leonid S; Wu, Hong-Wei; Wang, Hong et al. (2004) Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J Exp Med 199:1213-21
Shimada, Hiroyuki; Nakagawa, Atsuko; Peters, Julius et al. (2004) TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance. Cancer 101:1873-81
Metelitsa, L S; Weinberg, K I; Emanuel, P D et al. (2003) Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia 17:1068-77
Loza, Matthew J; Metelitsa, Leonid S; Perussia, Bice (2002) NKT and T cells: coordinate regulation of NK-like phenotype and cytokine production. Eur J Immunol 32:3453-62
Rudnick, E; Khakoo, Y; Antunes, N L et al. (2001) Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study. Med Pediatr Oncol 36:612-22
Metelitsa, L S; Naidenko, O V; Kant, A et al. (2001) Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J Immunol 167:3114-22
Seeger, R C; Reynolds, C P; Gallego, R et al. (2000) Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study. J Clin Oncol 18:4067-76
Nickerson, H J; Matthay, K K; Seeger, R C et al. (2000) Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. J Clin Oncol 18:477-86
Perez, C A; Matthay, K K; Atkinson, J B et al. (2000) Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study. J Clin Oncol 18:18-26
DuBois, S G; Kalika, Y; Lukens, J N et al. (1999) Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 21:181-9

Showing the most recent 10 out of 47 publications